Inside India’s Most Valued Pharma Company: Sun Pharma Chief Dilip Shanghvi Lays Out Future Growth Plans
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma chief will look for opportunities in emerging markets, but buyouts will not be large.
You may also be interested in...
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
After U.S. FDA Action, Investors Take Caraco To Court Alleging Violation Of Securities Laws
MUMBAI - A group of shareholders of U.S.-based generic drug maker Caraco Pharmaceutical has taken the company to court alleging that it violated securities laws by "recklessly disregarding May 29, 2008 and June 25, 2009 that their public statements concerning Caraco's business, operations and prospects were materially false and misleading." One of India's top generic drug makers, Sun Pharma, owns a majority 76 percent equity stake in Caraco